Matthew Karowe, MD
Gastroenterology · Boulder, CONPI 1851310478
Payments from drug & device makers
Across 150 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$943
- Gilead$418
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$334
- Bristol Myers Squibb$266
- QOL Medical, LLC$177
- Johnson & Johnson$144
- plus $472 from 10 others
What the payments were for
- Food & beverage$2,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $943 |
| Gilead | 22 | $418 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $334 |
| Bristol Myers Squibb | 15 | $266 |
| QOL Medical, LLC | 10 | $177 |
| Johnson & Johnson | 8 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Pfizer | 4 | $69 |
| UCB, Inc. | 3 | $60 |
| Merck | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 2 | $44 |
| Intercept Pharmaceuticals, Inc. | 2 | $32 |
| Shionogi Inc | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
How this compares
$2,754 in reported general payments places this provider in the 50th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $207,518 |
| Dexlansoprazole DrDexlansoprazole | 19 | $7,201 |
| Mesalamine | 18 | $4,830 |
| Budesonide DrBudesonide | 33 | $4,261 |
| Mesalamine ErMesalamine | 19 | $3,210 |
| Budesonide EcBudesonide | 11 | $1,715 |
| Famotidine | 91 | $1,328 |
| CholestyramineCholestyramine (With Sugar) | 12 | $665 |
| Pantoprazole Sodium | 96 | $619 |
| Omeprazole | 33 | $432 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $303 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boulder
- Barry MigicovskyBoulder$209K
- Bhaktasharan PatelColorado Springs$22M
- Marcelo KugelmasEnglewood$2.7M
- Douglas AdlerColorado Springs$1.2M
- Masi KhajaGrand Junction$1.2M
- Peter McNallyFt Carson$1.1M
- Mark GerichAurora$1M
- Raj ShahAurora$764K
- Rajesh JainLakewood$708K
- Steven EdmundowiczAurora$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.